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Edited by Lukas HuberAbstract Increased risk for the development of endometrial
cancer has been associated with unopposed oestrogen exposure,
hyperoestrogenic factors, and a history of breast cancer treated
long-term with tamoxifen (Tam). Stromal cell-derived factor-1,
currently named as CXCL12, is a chemokine that, via binding
to CXCR4 receptor, activates several downstream eﬀectors and
signalling pathways responsible for proliferation, survival, and
migration of cancer cells.
We observed that 17b-estradiol (E2) and tamoxifen (Tam) in-
crease the expression of CXCR4 and CXCL12 transcripts and
proteins in oestrogen receptor positive (ER+) but not in negative
(ER02) Ishikawa endometrial adenocarcinoma (ISH) cell lines.
However, the demethylating agent 5-Aza-2 0-deoxycytidine pro-
foundly elevated CXCR4 and CXCL12 expression in both ER+
and ER02 ISH cells. Bisulﬁte sequencing revealed that E2
and Tam up-regulate expression via demethylation of cytosine
in the cytosine–guanosine dinucleotide island of CXCR4 and
CXCL12 promoters. We also found that E2 and Tam signiﬁ-
cantly increased, for several hours, the expression of DNA meth-
yltransferase 3B4 enzymatically inactive splice variant in ER+
but not in ER02 ISH cells.
Our results suggest that E2 and Tam, through their ability for
gene-transcription regulation, change the cellular milieu that
maintains the hypermethylated stage of CpG islands of CXCR4
and CXCL12 promoters.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Endometrial cancer is a common malignant disease whose
morbidity frequency diﬀers among world regions [1]. Two
types of endometrial cancer have been recognized, and are dis-
tinguished according to their etiological and pathological fea-*Corresponding author. Fax: +48 61 8546510.
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disorder is type I, which is associated with expression of oest-
rogen and progesterone receptors, unopposed oestrogen expo-
sure, or other hyperestrogenic risk factors and endometrial
hyperplasia [2]. Type II is associated with atrophic endome-
trium, loss of oestrogen and progesterone receptors, high risk
of relapse, and metastatic disease [2]. One of the risk factors of
Type I endometrial tumor development is a history of breast
cancer and long term treatment with tamoxifen (Tam) [3].
Tam is a speciﬁc oestrogen receptor modulator (SERM),
which is exploited clinically for the treatment and prevention
of breast cancer [3]. In endometrium, Tam acts as a 17b-estra-
diol (E2) agonist that induces proliferation, cytoskeletal
remodeling, and migration of cells [4].
Stromal cell-derived factor-1 (SDF-1), now named CXCL12,
is a chemokine binds to CXCR4 receptor to chemoattract
numerous cell types during hematopoiesis and embryogenesis.
CXCR4 is a G-protein coupled receptor that is expressed con-
stitutively in a wide variety of normal tissues, including lym-
phatic tissues, thymus, brain and spleen [5]. CXCR4 was also
identiﬁed on the surface of cancer cells of the breast, stomach,
ovarian, lung, pancreas, prostate, and melanoma [6]. Binding
of CXCL12 to CXCR4 activates several downstream eﬀec-
tor molecule and, intracellular signalling pathways, and pro-
motes survival, proliferation, and migration of malignant
cells [6,7].
Expression of CXCR4 and CXCL12 is epigenetically regu-
lated by methylation of cytosine in cytosine-guanosine (CpG)
dinucleotides located in promoter sequence [8,9]. DNA meth-
ylation is performed by DNA methyltransferases (DNMTs)
that are divided into DNMT1, DNMT3A and DNMT3B.
DNMT1 is involved in the maintenance of DNA methylation,
whereas DNMT3A and DNMT3B belong to de novo DNMTs
[10]. The DNMT3B isoforms are expressed as alternatively
spliced variants DNMT3B1, DNMT3B2, DNMT3B3 and
DNMT3B4, that exhibit diﬀerent integrity of the catalytic site
[11,12]. DNMT3B4 splice variant does not possess conserved
DNMT motifs, and may function as a negative regulator of
DNA methylation [13].
We investigated the eﬀect of E2, Tam, and 5-Aza-2 0-deoxy-
cytidine (5-dAzaC) on CXCL12 and CXCR4 expression in po-
sitive oestrogen receptor Ishikawa human Asian endometrial
adenocarcinoma (ER+ISH) cells and negative oestrogen
receptor Ishikawa (Heraklio) 02 human endometrial adenocar-
cinoma (ER02 ISH) cells.blished by Elsevier B.V. All rights reserved.
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2.1. Reagents and antibodies
E2, Tam and 5-dAzaC were purchased from Sigma–Aldrich Co. (St.
Louis, MO). Goat polyclonal (Gp) anti-fusin antibody (Ab) (A-17),
Gp anti-DNMT3B Ab (T-16), Gp anti-DNMT1 Ab (C-17), Gp anti-
DNMT3A (D-15), Gp anti-SDF-1 Ab (C-19) mouse anti-goat
horseradish peroxidase (HRP)-conjugated Ab, donkey anti-goat
HRP-conjugated Ab, anti-actin HRP-conjugated Ab (clone I-19), don-
key anti-goat IgG-ﬂuorescein isothiocyanate (FITC), donkey, and goat
serums and UltraCruz Mounting Medium were provided by Santa
Cruz Biotechnology (Santa Cruz, CA). Allophycocyanin (APC)-conju-
gated anti-hCXCR4 mouse Ab and isotype control Ab were purchased
from R&D Systems (Minneapolis, MN) and from Caltag Laborato-
ries, (Burlingame, CA), respectively. BD GolgiPlug was purchased
from BD Bioscience (Franklin Lakes, NJ).
2.2. Cell culture
ER+ ISH and ER02 ISH cell lines [14] were obtained from the Euro-
pean Collection of Cell Cultures. These cell lines were maintained in
DMEM GibcoBRL (Grand Island, NY) medium containing 5% heat-
inactivated fetal bovine serum (FBS) and 2 mM glutamine in tissue cul-
ture ﬂasks. To determine the eﬀect of E2 and Tam on CXCR4 and
CXCL12 expression, the ER+ ISH and ER02 ISH cells were main-
tained for 24 h in phenol red-free DMEM GibcoBRL (Grand Island,
NY) medium supplemented with 5% charcoal-dextran-stripped calf ser-
um from Sigma–Aldrich Co. (St. Louis, MO). The ER+ and ER02
ISH cells were cultured for 48 h in the absence or in the presence of
E2 (5.0, 10.0 nM ), Tam (0.5, 1.0 lM ) or 5-dAzaC (0.33, 1.0 lM). Then
these cells were used for total RNA isolation, western blotting, ﬂow
cytometric, immunoﬂuorescent analysis and sodium bisulﬁte sequenc-
ing of CpG island region of CXCR4 and CXCL12 promoter.
2.3. Real-time quantitative PCR (RQ-PCR) analysis of CXCR4,
CXCL12 and DNMT3B variant transcript levels in ER+ and
ER02 ISH cells
Total RNA was isolated according to the method of Chomczynski
and Sacchi [15]. RNA samples were treated with DNase I, quantiﬁed,
and reverse-transcribed into cDNA using oligo-dT primers. RQ-PCR
was conducted in a Light Cycler real-time PCR detection system from
Roche Diagnostics GmbH, (Mannheim, Germany) using SYBR
Green I as detection dye. Target cDNA was quantiﬁed using relative
quantiﬁcation method. The quantity of CXCR4 and CXCL12 tran-
scripts in each sample was standardized by human mitochondrial ribo-
somal protein L19 (hMRPL19) and RNA polymerase 2A subunit
(POLR2A) transcript levels [16]. For ampliﬁcation, 2 ll of total
(20 ll) cDNA solution was added to 18 ll of QuantiTect SYBER
Green PCR Master Mix from QIAGEN GmbH (Hilden, Germany)
and primers (Table 1, Fig. 4). One RNA sample of each preparation
was processed without RT-reaction to provide a negative control in
subsequent PCR. RQ-PCR results were expressed as number of copies
per lg of total RNA or percentage of their respective controls.
2.4. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) and western blotting analysis
ER+ and ER02 ISH cells were cultured in the absence or in the pres-
ence of E2 (10.0 nM), Tam (1.0 lM) and 5-dAzaC (1.0 lM) for 48 h fol-
lowed by treatment in lysis RIPA buﬀer. Next, 20lg of protein wereTable 1
Oligonucleotide sequences used for RQ-PCR analysis
Primer Sequence (50-30 direction)
POLR2A CTGGAGACAGCAAGGTCGTCC CCAGCTTCTTGCTCAATTC
hMRPL19 ACTTTATAATCCTCGGGTC ACTTTCAGCTCATTAACA
CXCR4 TTCTTAACTGGCATTGTGGG GAAGCGTGATGACAAAGAGG
CXCL12 GTGCCCTTCAGATTGTAGC GTCTTTGCCCTTTCATCTC
DNMT3B1 GCAGGCAGTAGGAAATTAGA TTCATCCCCTCGGTCTTTG
DNMT3B2 AGGATAGCCAAGTTAAAGAAAG TGCACAGGAAAGCCAAAG
DNMT3B3 ATGAACAGGATCTTTGGCTTT CGGATGACAGGCACGCTC
DNMT3B4 TGAACAGTTAAAGAAAGTACAG TGCACAGGAAAGCCAAAG
DNMT3B1, DNMT3B2, DNMT3B3, and DNMT3B4 include main splice vresuspended in sample buﬀer and separated on 10% Tris-glicyne gel
using SDS–PAGE. Gel proteins were transferred to nitrocellulose,
which was blocked with 3% milk in Tris buﬀered saline/Tween. The
immunodetection was performed with Gp anti-fusin Ab (A-17), Gp
anti-DNMT3B Ab (T-16), anti-DNMT1 Ab (C-17) or Gp anti-
DNMT3A (D-15) followed by incubation with mouse anti-goat HRP-
conjugated Ab or donkey anti-goat HRP-conjugated Ab, respectively.
The membranes were reblotted with anti-actin HRP-conjugated Ab
(clone I-19) to ensure equal protein loading of the lanes. Bands were re-
vealed using ECL kit and Hyperﬁlm ECL Amersham (Piscataway, NJ).
2.5. Flow cytometric analysis of CXCR4 expression
ER+ and ER02 ISH cells were cultured in the absence or in the
presence of E2 (10.0 nM), Tam (1.0 lM) and 5-dAzaC (1.0 lM) for
48 h, followed by incubation for 30 min with APC-conjugated anti-
hCXCR4 mouse Ab or appropriate isotype control Ab in phosphate-
buﬀered saline (PBS), containing 2% FCS and 0.1% sodium azide
(PBS/FCS). The cells were then washed three times in PBS/FCS and
were immediately analyzed on FACSCanto Flow Cytometer (Bec-
ton-Dickinson, San Jose, CA, USA).
2.6. Immunoﬂuorescence
ER+ and ER02 ISH cells were cultured in the absence or in the
presence of E2 (10.0 nM), Tam (1.0 lM) and 5-dAzaC (1.0 lM) for
48 h. Cells were cultured in the presence BD GolgiPlug in concentra-
tion of 1 ll per 1 ml of culture medium for the last 6 h. Cells were then
tripsinised and spinned on glass coverslips coated with polylysine and
ﬁxed for 10 min in 20 C methanol/acetone (1:1). Non-speciﬁc bind-
ing sites were blocked for 1 h at room temperature with 10% donkey
serum / PBS followed by incubation with the Gp anti-SDF1(C-19)
Ab or 3% goat serum overnight at 4 C. Cells were washed three times
with PBS and incubated with the donkey anti-goat Ab conjugated
with-FITC. Following three washes with PBS, coverslips were
mounted with UltraCruz Mounting Medium with DAPI, and ana-
lyzed under ﬂuorescence microscope Olympus BX41 (Tokyo, Japan).
2.7. Sodium bisulﬁte DNA sequencing of CXCR4 and CXCL12
promoter region containing CpG islands
Genomic DNA was extracted by salt method, and DNA cytosine
bases were converted to uracil according to EZ DNA Methylation
Kit procedure from Zymo Research Corporation (Orange, CA).
To determine the location of CpG islands in the promoter region of
CXCR4 and CXCL12, we used a program available online: http://
www.ebi.ac.uk/emboss/cpgplot/. The CXCR4 and CXCL12 promoter
regions containing CpG islands were ampliﬁed from the bisulﬁte-mod-
iﬁed DNA by pair of primers: 5 0GGG AGA GTG AGG AAA TGA
AA3 0 (forward, nt 1070 to 1090) 5 0AAG ATT GGT AGG TGT
AAG TG3 0 (reverse, nt 797, 817), and 5 0TTT TTT GTT TTG
TTT GTA TAG G3 0 (forward, 789, 812), 5 0GGT TTT GTT
ATA GGG ATA ATA3 0 (reverse-, nt 559, 585), complementary
to the bisulﬁte-DNA modiﬁed sequence, respectively. PCR ampliﬁca-
tion was performed by FastStart Taq DNA Polymerase from Roche
Diagnostic GmbH (Penzberg, Germany).
2.8. Statistical analysis
Data groups were analyzed by ANOVA to evaluate if there was sig-
niﬁcance (P < 0.05) between the groups. For all experimental groups,
which contented the initial ANOVA criterion, individual comparisonsNCBI number
www.ncbi.nih.gov
Product
size (bp)
Reaction
eﬃciency (%)
C NM_000937 147 96
NM_014763 171 96
NM_003467 135 97
NM_199168 186 96
NM_006892 147 96
ATC NM_175848 152 96
NM_175849 107 96
AT AF129268 147 96
ariant of DNMT3B (Fig. 4) [12,13].
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assumption of two-tailed distribution and two samples with equal var-
iance at the P < 0.05 level. Statistical signiﬁcance is marked by aster-
isks in the ﬁgures.3. Results
3.1. E2 and Tam increase the transcription of CXCR4 and
CXCL12 in ER+ but not in ER02 ISH cells. CXCL12
protein was detected in ER+ but not ER02 ISH cells
treated with E2 and Tam
We observed that E2 and Tam, similarly to the demethylat-
ing agent 5-dAzaC, profoundly elevated transcription of
CXCR4 and CXCL12 in ER+ ISH cells (Fig. 1A). E2 and
Tam resulted in 1.8- to 4.2-fold and 2.3- to 7.0-fold increase,
respectively, in the transcription of CXCR4 in ER+ ISH cells
(Fig. 1A). We also found that E2 and Tam increased in 1.6-
to 2.4-fold and 1.8- to 5.0-fold the transcription of CXCL12Fig. 1. E2 and Tam up-regulate CXCR4 and CXCL12 transcripts in ER+ (A
free medium either in the absence (CN) or in the presence of aE2 (5.0 nM), bE2
dAzaC (1.0 lM) for 48 h. After incubation, cells were used for total RNA isol
transcripts, and CXCL12 protein immunoﬂuorescene analysis. RQ-PCR resul
expressed as number of copies per lg of total RNA. Each sample was de
experiments, *P < 0.05. The RQ-PCR ampliﬁcation products of cDNA from
bromide, visualized under UV light, and photographed.
Fig. 2. E2 and Tam up-regulate CXCL12 protein in ER+ ISH cells. For im
(results not shown) ISH cells were prepared as follows: cells were cultured in a
(1.0 lM). For the last 6 h ISH cells were cultured in medium containing BD
incubated with 3% goat serum (CNGS) or the Gp anti-SDF1 Ab and donke
with DAPI, and analyzed under ﬂuorescence microscope.in ER+ ISH cells, respectively (Fig. 1A). E2 and Tam did
not change transcription of CXCR4 and CXCL12 in ER02
ISH cells (Fig. 1B). However, the demethylating agent 5-dA-
zaC resulted in pronounced increase in the expression of
CXCR4 and CXCL12 in both ER+ and ER02 ISH cells
(Fig. 1A and B). Using immunoﬂuorescence analysis we also
observed that E2, Tam and 5-dAzaC increased the CXCL12
protein content in ER+ ISH (Fig. 2). However, we did not ﬁnd
an increase in CXCL12 biosynthesis in ER02 ISH cells trea-
ted by E2 or Tam (results not shown).3.2. Eﬀect of E2 and Tam on CXCR4 protein level in ER+
and ER02 ISH cells
Western blotting analysis revealed that E2 and Tam elevated
cellular levels of CXCR4 protein in ER+ but not in ER02
ISH cells (Fig. 3A and B). This eﬀect of E2 and Tam was asso-
ciated with approximately 3 and 6 fold elevation of CXCR4
densities on surface of ER+ ISH cells, respectively (Fig. 3C).) but not in ER02 ISH cells (B). ISH cells were cultured in phenol red-
(10.0 nM), aTam (0.5 lM), bTam (1.0 lM), a5-dAzaC (0.33 lM) or b5-
ation, reverse transcription RQ-PCR analysis of CXCR4 and CXCL12
ts were standardized by hMRPL19 and POLR2A. cDNA levels and are
termined in triplicate and results represent means ± S.E. from three
30 cycles were analyzed on 2.5% agarose gels, stained with ethidium
munoﬂuorescence analysis of CXCL12 protein in ER+ and in ER02
bsence (CN) or presence of E2 (10.0 nM), Tam (1.0 lM) and 5-dAzaC
GolgiPlug. Then cells were ﬁxed with methanol/acetone and were
y anti-goat Ab conjugated with-FITC washed with mounting medium
Fig. 3. E2 and Tam increase the CXCR4 cellular content and cell surface density of CXCR4 in ER+ (A, C) but not in ER02 (B, D) ISH cells. ISH
cells were cultured in phenol red-free medium either in the absence (CN) or in the presence of E2 (10.0 nM), Tam (1.0 lM) or 5-dAzaC (1.0 lM) for
48 hrs followed by western blotting (A, B) or ﬂow cytometry (C, D) analysis. Cell proteins were separated by SDS–PAGE, transferred to a membrane
that was immunoblotted with Gp anti-CXCR4 Ab, mouse anti-goat HRP-conjugated Ab and, to equalize protein loading, reblotted with anti-actin
HRP-conjugated Ab. For ﬂow cytometry analysis, cells were incubated with APC-conjugated anti-hCXCR4 mouse Ab or appropriate isotype
control Ab, washed, and analysed on FACSCanto Flow Cytometer. The white (CN) and grey colored histograms represent surface density of
CXCR4 in ER+ and ER02 ISH cells cultured either in the absence or in the presence of E2 , Tam or 5-dAzaC, respectively.
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protein in ER02 ISH cells (Fig. 3B and D). However, 5-dA-
zaC increased in CXCR4 protein content and densities on the
surface of both ER+ and ER02 ISH cells (Fig. 3A–D).
3.3. E2 and Tam signiﬁcantly up-regulate DNMT3B4 splice
variant expression in ER+ but not in ER02 ISH cells
We found that E2 and Tam treatment resulted in several
hours’ increase in transcript and protein levels of DNMT3B3
and DNMT3B4 variants in ER+ ISH cells (Fig. 5A, C and
D). We observed gradual increase of DNMT3B3 andFig. 4. Scheme of DNMT3B and their splice variants structure
DNMT3B is composed of a regulatory N-terminal and an active site
containing C-terminal domain [9]. DNMT3B2, DNMT3B3, and
DNMT3B4 isoforms do not contain exons 10 and 11 in their mRNA
sequences. Moreover, DNMT3B3 and DNMT3B4 lack exons 21–22 or
21, respectively. DNMT3B4 is considered an inactive isoform func-
tioning as a negative regulator of DNA methylation [12,13]. Arrows
represent positions of primers distinguishing DNMT3B transcript
variants (Table 1).DNMT3B4 splice variant transcript levels that reached a max-
imum at the sixth hour of E2 and Tam treatment. The
DNMT3B4 transcript variant was most profoundly up-regu-
lated among all DNMT3B splice variants (Fig. 5A). After
the next 30 h, DNMTB3 and DNMTB4 transcript and protein
contents reached the level observed in the control (Fig. 5A, C
and D). In contrast, the transcripts of DNMT3B1 and
DNMT3B2 splice variants were increased very slightly in
ER+ ISH cells (Fig. 5A). However, we did not observe any
E2 or Tam eﬀect on DNMT3B splice variant transcript
(Fig. 5B) and protein (results not shown) levels in ER02
ISH cells. We also observed that 5-dAzaC resulted in complete
depletion of DNMT1 and strong depletion of DNMT3B in
ER+ and ER02 ISH cells (Fig. 5E).3.4. Bisulﬁte DNA sequencing reveals that E2 and Tam,
similarly to 5-dAzaC, resulted in demethylation of CpG
islands of CXCR4 and CXCL12 promoters
We found that E2 and Tam promote approximately 95%
demethylation of the CpG dinucleotide island in the region
of CXCR4 promoter from 817 to 1070 in ER+ ISH cells
(Table 2A). We also observed that E2 and Tam caused 86%
demethylation of CXCL12 promoter sequence located from
559 to 812 in ER+ ISH cells (Table 2A). E2 and Tam did
not cause demethylation of the same CXCR4 and CXCL12
promoter regions in ER02 ISH cells (Table 2A and B). How-
ever, incubation of ER+ and ER02 ISH cells in medium with
5-dAzaC resulted in a similar level of demethylation of
CXCR4 and CXCL12 promoter region as E2 and Tam treat-
ment in ER+ ISH cells (Table 2A and B).
Fig. 5. E2 and Tam up-regulate DNMT3B4 mRNA (A) and protein (C, D) in ER+ but not in ER02 (B) ISH cells. Eﬀect of 5-dAzaC on DNMT1
and DNMT3B depletion in ER+ and ER02 ISH cells (E). ISH cells were cultured in phenol red-free medium either in the absence or in the presence
of E2 (10.0 nM) or Tam (1.0 lM) for 0 h, 0.5 h, 1.0 h, 3.0 h, 6.0 h, 12.0 h, 24.0 h, and 36 h. After incubation, the cells were used for RQ-PCR and
western blotting analysis of DNMT3B variant expression. RQ-PCR results were standardized by hMRPL19 cDNA levels and were expressed as
percentage of their respective controls. Results are representative of three separate experiments and are means of triplicate values with S.E. < 10%;
*P < 0.05. For western blotting analysis, ER+ (C, D) and ER02 (not shown) ISH cell proteins were separated by SDS–PAGE, and transferred to a
membrane that was then immunoblotted with Gp Ab anti-DNMT3B Ab, secondary donkey anti-goat HRP-conjugated Ab and, to equalize protein
loading, reblotted with anti-actin HRP-conjugated Ab. To determine the eﬀect of 5-dAzaC on DNMT1 and DNMT3B the ER+ ISH and ER02 ISH
cells were cultured for 48 h in absence or in presence of 5-dAzaC (1.0 lM), and subsequently used for western blotting analysis of these DNMTs (E).
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Oestrogens exhibit a broad range of physiological functions
encompassing regulation of the menstrual cycle, reproduction
and anabolic eﬀect to bone, skin, skeletal muscle, brain, and
cholesterol mobilization [3]. However, hormone therapy in
postmenopausal women exploiting unopposed oestrogen treat-
ment and adjuvant therapy for breast cancer using SERMs,
particularly Tam, have a markedly increased risk of endome-
trial cancer development [2,17].
Our studies indicate that E2 and especially Tam signiﬁcantly
increase the expression of CXCR4 and CXCL12 in ER+ ISH
cells, which has been associated with temporary elevation of
DNMT3B4 splice variant expression and promoter region
CpG island demethylation (Table 2, Figs. 1–3 and 5). There
was no increase in expression of CXCR4 and CXCL12 in
ER02 ISH cells, suggesting that E2 and Tam binding to oest-
rogen receptors could mediate events leading to promoter
demethylation in ER+ ISH cells (Table 2, Figs. 1–3 and 5).Nevertheless, Tam exhibits anti-oestrogenic function in the
breast, and also displays partial oestrogenic eﬀects in endome-
trium cells [3,17]. Recently, studies using human genome
microarrays showed that Tam was able to increase the expres-
sion of numerous genes in endometrial carcinomas [18] (Gene
Expression Omnibus GSE3013). E2 and Tam are also able to
activate protein kinase AKT, as well as cytoskeletal remodel-
ing and migration of endometrial cancer cells [6,19].
We observed that Tam has a strong eﬀect on up-regulation of
CXCR4 and CXCL12 expression than E2, on in ER+ ISH cells
(Figs. 1–3).Mizokami et al. andwe (not shown) detected expres-
sion of CXCR4 and CXCL12 in primary endometrial tumour
cells [20]. This suggests signiﬁcant E2 or Tam role in CXCR4
and CXCL12 expression increase contributing to immortality
and metastasis of endometrial carcinoma cells in vivo.
CXCR4 and CXCL12 interaction stimulates the phosphati-
dylinositol-3-kinase (PI3K), which activates protein kinase
AKT in cancer cells. Activated AKT has been implicated in
anti-apoptosis and may have a proliferative eﬀect on various
Table 2
Methylation patterns of CpG islands of CXCR4 (A) and CXCL12 (B) promoters in ER+ and ER02 ISH cells treated with E2, Tam and 5-dAzaC
CpGnumber
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
(A)
Position + 1 817 836 856 860 888 897 899 907 912 922 927 930 932 951 958 962 971 985 992 997 1029 1037 1043 1046 1048 1052 1065 1067 1070
ER+ISH CN + +  + + +  + + + + + · + + +  + + /+ + +  /+ + · + ·
ER ISH +E2   + +       · /+    ·  /+    +  +   /+  ·
ER+ISH Tam     /+ +    ·   /+     /+    +   +    /+
ER+ISH
5-dAzaC
  /+    · +           +      ·   
ERISH CN + + + + + + /+ + + + + + /+ + + +  + + + + + + · + + + +/ +
ERISH E2 + · + + + + + + +  + + + · + /+ + + + · + + +  + /+ + + +
ERISH
Tam
+ + /+ +  + + + /+ + + + + +  + + /+ + + /+ + · +  + + + +
ERISH
5-dAzaC
      /+    ·       /·         · 
CpGnumber
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
(B)
Position + 1 585 589 604 600 614 646 662 673 680 683 689 692 702 709 722 737 744 759 762 772 788
ER+ISH CN + +  +  + /+ + + +  + + + +/ + + + + + +
ER ISH +E2   /+     +       +/     + 
ER+ISH Tam       /+     ·         
ER+ISH
5-dAzaC
   /+   ·       ·     /+  
ERISH CN + + + + + + + + + + + + /+ + + +  + + + +
ERISH E2 + + + /+ + + · + + + + +  + + + + + + /+ +
ERISH Tam + + + + · + + + /+ + + + + +  + + + + + +
ERISH
5-dAzaC
    ·       /+ /+        
Abbreviations: +, methylated; , unmethylated; /+, heterozygous; ·, undetermined. ISH cells were cultured in phenol red free medium for 48 h in the absence (CN) or in the presence of E2 (10 nM), Tam (1 lM) or 5-dAzaC (1 lM). Direct sequencing of the 401 and 252 bp of bisulﬁte
sequencing PCR product (BSPP) primers indicated the methylation status of 29 and 21 CpG dinucleotides for CXCR4 (A) and CXCL12 (B) promoters, respectively. The location of each CpG dinucleotide according to the CXCR4 and CXCL12 transcriptional start (+1) is indicated.
Data are representative of sequence analysis from three independent BSPP analyses.
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Ł. Kubarek, P.P. Jagodzinski / FEBS Letters 581 (2007) 1441–1448 1447types of cancer cells, therefore this pathway is also crucial for
immortality of endometrial cancer type I [19]. Activation of
AKT kinase in endometrial cells is decreased by phosphatidyl-
inositol phosphate phosphatase PTEN tumor suppressor
genes, which are often genetically or epigenetically inactivated
in endometrial cancer type I [21]. The mitogen-activated pro-
tein (MAP) kinase pathway is the next signal transduction
pathway that is controlled by binding of CXCL12 to CXCR4.
The MAP kinase pathway increases the biosynthesis of pro-
teins responsible for proliferation and survival of cancer cells
[7]. Binding of CXCL12 to CXCR4 also promotes polymeriza-
tion of actin and induces cell migration [6].
The up-regulation of CXCR4 and CXCL12 expression via
DNA demethylation of promoters was already identiﬁed in
melanoma and colon cancer cells, respectively [8,9]. Our inves-
tigations indicate that E2 and Tam in ER+ endometrial cancer
can increase the expression of CXCR4 and CXCL12 by
demethylation of CpG islands of promoters.
Recently, it has been found that EGLN1 prolyl hydroxylase
is mutated with signiﬁcant frequency in endometrial cancers,
including ISH cells [22]. EGLN1 down-regulates Hipoxa
inducible factor (HIF)-1a by recruiting von Hippel-Lindau
protein. However, EGLN1 mutation is responsible for impair-
ing this process and abundant presence of HIF-1a in ISH cells
[22]. HIF-1a binds to promoter sequence of CXCR4, located
at position 1.3 kbp upstream of transcriptional start, and
considerably increases expression of CXCR4 [23]. We deter-
mined DNA is demethylated in promoter region from 817
to 1070 bp, which borders with the binding site of HIF-1a.
Methylated DNA can recruit MeCP1 megadalton protein
complex to several nucleosomes, resulting in deacetylation
and remodeling of neighboring chromatin regions to hetero-
chromatin [24]. Demethylation of promoter region from
817 to 1070 bp may prevent heterochromatin formation
and may results in an increase in the binding of HIF-1a and
increased expression of CXCR4.
Recently, PAX2 has been identiﬁed as a relevant eﬀector of
E2 and Tam in endometrial carcinoma [18]. Pax gene expres-
sion is developmentally regulated and is epigenetically silenced
in adulthood, but this silencing methylation is lost in 75% of
endometrial carcinomas [18]. However, it has not been clear
what kind of mechanism is responsible for demethylation of
genomic CpG islands of promoters in proliferating cells.
We did not observe changes in expression of DNMT1 and
DNMT3A in ER+ and ER02 ISH cells treated by E2 or
Tam (not shown). However, we found that only ER+ ISH cells
treated by E2 or Tam exhibited a temporary 4-fold increase of
DNMT3B4 expression with a peak at 6 h (Fig. 5A, C and D).
The DNMT3B4 variant does not contain conservative se-
quences responsible for enzymatic activity and is believed to
act in negative regulation of DNA methylation [13]. During
replication, DNMT3B4 protein may shield CpG dinucleotide
in the newly-synthesized DNA strand for accessibility of
DNMT1. This would be consistent with the prior observation
that overexpression of DNMT3B4 is associated with DNA
hypomethylation on pericentromeric satellite regions in human
hepatocarcinogenesis [13].
The eﬀect of DNMT3B4 on DNA demethylation can also be
supported by the observation that inhibitor of DNMTs 5-dA-
zaC results in complete depletion of DNMT1 and strong
depletion of DNMT3B in ISH and other malignant cells
(Fig. 5E) [11].Our investigation suggests that E2 and Tam, through their
ability to regulate gene transcription, change the cellular milieu
that maintains the hypermethylated stage of various genes. Fu-
ture studies are needed to investigate detailed mechanism by
which E2 and Tam result in demethylation of CXCR4 and
CXCL12 promoters and whether hormone-dependent loss of
methylation is unique for endometrial cancer cells.
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